2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Chiome Bioscience Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. CBA-1535, CBA-1535+Pembrolizumab - Solid Tumors, Refractory Cancer | Phase 1 | Recruiting | Chiome Bioscience Inc. | 70 | 2022-06-27 | 2025-06-12 |
| A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3 - Solid Tumors, Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Chiome Bioscience Inc. | 66 | 2020-06-01 | 2026-06-17 |
Neoplasms (2) · Carcinoma, Hepatocellular (1) · Melanoma (1)
Japan (2)